Teriparatide for Postsurgical Hypoparathyroidism


  • Study type

  • Study phase

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

  • Site IRB
    • Rochester, Minnesota: 10-000901
    NCT ID: NCT01171690
    Sponsor Protocol Number: 10-000901

About this study

Will teriparatide ( Forteo) shorten the length of hospitalization post thyroidectomy in patients with symptomatic hypoparathyroidism

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion criteria:

  • Patients post bilateral thyroid bed surgery (cancer, Graves' disease, multinodular goiter)
  • Symptomatic hypocalcemia
  • Total calcium < 8 mg/dL persisting after 24 hours of therapy with calcitriol (minimum 0.25 mcg twice a day) and calcium supplementation (minimum 1.5 grams of elemental calcium per day)
  • Parathyroid hormone (PTH) level below low end of normal range

Exclusion criteria:

  • Renal failure
  • Any prior parathyroid pathology
  • Pre-existing hypercalcemia
  • Metabolic bone diseases other than osteoporosis
  • Paget's disease
  • Ongoing therapy with Forteo for osteoporosis
  • Active non-thyroidal malignancy or suspicion of residual thyroid malignancy
  • History of skeletal malignancies, primary or metastatic
  • Pregnancy
  • Active or recent urolithiasis
  • Digitalis therapy
  • Patients at increased baseline risk for osteosarcoma, i.e. family history of osteosarcoma or prior radiation therapy involving the skeleton
  • Pediatric populations
  • Unexplained elevations of alkaline phosphatase

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Marius Stan, M.D.

Closed for enrollment

Contact information:

Marius Stan M.D.




Mayo Clinic Footer